Targeted therapies in multiple myeloma
Efstathios Kastritis1, Andreas Charidimou, Andreas Varkaris
1Department of Clinical Therapeutics, University of Athens School of Medicine, Alexandra Hospital, 80 Vas Sofias Ave, 115 28, Athens, Greece. stathiskastritis@yahoo.com
Abstract:
Increasing knowledge of the biology of multiple myeloma led the way for the development of novel drugs that have changed the management of the disease. New treatments target not only to the malignant plasma cell but also target the interactions of myeloma cells with their microenvironment. Several preclinical studies have identified potential targets and drugs are developed that act on pathways crucial for myeloma cell survival, proliferation, migration and drug resistance. The identification of active agents in the laboratory is followed by rationally designed clinical studies that validate these drugs, either as single agents or in combinations with other active drugs. These novel agents may be either small molecules or monoclonal antibodies targeting receptors, kinase activity of receptors or key molecules within critical pathways, intracellular maintenance mechanisms and immune modulation.
Insights
Novel drugs targeting multiple myeloma cells and their microenvironment have transformed disease management. Research focuses on small molecules and monoclonal antibodies for improved patient outcomes.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Multiple myeloma (MM) is a hematologic malignancy characterized by uncontrolled proliferation of plasma cells.
- Advances in understanding MM biology have paved the way for novel therapeutic strategies.
- Current treatments aim to target not only malignant plasma cells but also their supportive microenvironment.
Purpose of the Study:
- To review the development and application of novel drugs in multiple myeloma management.
- To highlight therapeutic strategies targeting myeloma cells and their microenvironment.
- To discuss the role of preclinical studies and clinical trials in validating new agents.
Main Methods:
- Review of preclinical studies identifying novel drug targets in multiple myeloma.
- Analysis of clinical trial data for novel agents (small molecules, monoclonal antibodies) in MM.
- Examination of drugs targeting key pathways, intracellular mechanisms, and immune modulation.
Main Results:
- Novel drugs targeting myeloma cells and their microenvironment have significantly altered disease management.
- Preclinical research has identified numerous potential therapeutic targets.
- Clinical studies are validating these agents as single agents or in combination therapies.
Conclusions:
- Targeted therapies, including small molecules and monoclonal antibodies, represent a paradigm shift in multiple myeloma treatment.
- Understanding the complex interactions within the myeloma microenvironment is crucial for developing effective therapies.
- Ongoing research and clinical trials continue to refine treatment strategies for multiple myeloma.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:27Tumor Immunotherapy
01:24Modified-Release Drug Delivery Systems: Site-Targeted
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...